BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26657401)

  • 1. Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.
    Mayati A; Bruyere A; Moreau A; Jouan E; Denizot C; Parmentier Y; Fardel O
    PLoS One; 2015; 10(12):e0144667. PubMed ID: 26657401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
    Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
    PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium.
    Deutsch B; Neumeister C; Schwantes U; Fromm MF; König J
    Mol Pharm; 2019 Feb; 16(2):510-517. PubMed ID: 30656943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
    Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
    Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters.
    Jensen O; Rafehi M; Tzvetkov MV; Brockmöller J
    Biochem Pharmacol; 2020 Jan; 171():113731. PubMed ID: 31783011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1.
    Li L; Song F; Tu M; Wang K; Zhao L; Wu X; Zhou H; Xia Z; Jiang H
    Int J Pharm; 2014 Apr; 465(1-2):5-10. PubMed ID: 24530383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.
    Chedik L; Bruyere A; Le Vee M; Stieger B; Denizot C; Parmentier Y; Potin S; Fardel O
    PLoS One; 2017; 12(1):e0169480. PubMed ID: 28099443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.
    van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB
    Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.
    Jonker JW; Wagenaar E; Van Eijl S; Schinkel AH
    Mol Cell Biol; 2003 Nov; 23(21):7902-8. PubMed ID: 14560032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional mapping of rbOCT1 and rbOCT2 activity in the S2 segment of rabbit proximal tubule.
    Kaewmokul S; Chatsudthipong V; Evans KK; Dantzler WH; Wright SH
    Am J Physiol Renal Physiol; 2003 Dec; 285(6):F1149-59. PubMed ID: 12944320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
    Nies AT; Herrmann E; Brom M; Keppler D
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP.
    Schlatter E; Mönnich V; Cetinkaya I; Mehrens T; Ciarimboli G; Hirsch JR; Popp C; Koepsell H
    J Membr Biol; 2002 Oct; 189(3):237-44. PubMed ID: 12395288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
    Luo L; Ramanathan R; Horlbogen L; Mathialagan S; Costales C; Vourvahis M; Holliman CL; Rodrigues AD
    Anal Chem; 2020 Jul; 92(14):9745-9754. PubMed ID: 32551505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.
    Choi MK; Song IS
    Biopharm Drug Dispos; 2012 Apr; 33(3):170-8. PubMed ID: 22415520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.
    Duan H; Hu T; Foti RS; Pan Y; Swaan PW; Wang J
    Drug Metab Dispos; 2015 Nov; 43(11):1773-80. PubMed ID: 26285765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
    Müller F; König J; Hoier E; Mandery K; Fromm MF
    Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.